TEV Panoramica delle azioni Teva Pharmaceutical Industries Limited sviluppa, produce, commercializza e distribuisce farmaci generici e di altro tipo e prodotti biofarmaceutici negli Stati Uniti, in Europa, in Israele e a livello internazionale. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Catturate i vostri pensieri, i link e la narrativa aziendale
Teva Pharmaceutical Industries Limited Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Teva Pharmaceutical Industries Prezzi storici delle azioni Prezzo attuale dell'azione US$16.30 Massimo di 52 settimane US$21.90 Minimo di 52 settimane US$11.50 Beta 0.71 Variazione di 1 mese -19.70% Variazione a 3 mesi 1.88% Variazione di 1 anno 35.83% Variazione a 3 anni 118.79% Variazione a 5 anni 43.49% Variazione dall'IPO -42.48%
Notizie e aggiornamenti recenti Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2025
Teva Pharmaceutical Industries Limited to Report Q4, 2024 Results on Jan 29, 2025 Dec 21
Third quarter 2024 earnings released: US$0.39 loss per share (vs US$0.071 profit in 3Q 2023) Nov 08
Teva Pharmaceuticals Limited Unveils New Phase 3 Positive Results for Olanzapine Lai, and Presents Real-World Data on Uzedy At Psych Congress 2024 Nov 04
Alvotech and Teva Pharmaceutical Industries Ltd. Announce U.S. FDA Approval of Additional Presentation of SELARSDI (ustekinumab-aekn) Oct 22
Teva Pharmaceutical Industries Limited to Report Q3, 2024 Results on Nov 06, 2024 Oct 01 Vedi altri aggiornamenti Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2025
Teva Pharmaceutical Industries Limited to Report Q4, 2024 Results on Jan 29, 2025 Dec 21
Third quarter 2024 earnings released: US$0.39 loss per share (vs US$0.071 profit in 3Q 2023) Nov 08
Teva Pharmaceuticals Limited Unveils New Phase 3 Positive Results for Olanzapine Lai, and Presents Real-World Data on Uzedy At Psych Congress 2024 Nov 04
Alvotech and Teva Pharmaceutical Industries Ltd. Announce U.S. FDA Approval of Additional Presentation of SELARSDI (ustekinumab-aekn) Oct 22
Teva Pharmaceutical Industries Limited to Report Q3, 2024 Results on Nov 06, 2024 Oct 01
Second quarter 2024 earnings released: US$0.75 loss per share (vs US$0.77 loss in 2Q 2023) Aug 01 Teva Pharmaceuticals and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease Jul 25
Teva Pharmaceutical Industries Limited Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY (fremanezumab) Space Trial for Prevention of Episodic Migraine Jul 18
Teva Pharmaceutical Industries Limited to Report Q2, 2024 Results on Jul 31, 2024 Jul 04
Teva Pharmaceutical Industries Ltd Announces New AJOVY® (Fremanezumab) Migraine Prevention Data Challenges Treatment Pauses Jun 29
Teva Pharmaceutical Industries Limited Announces Launch of Authorized Generic of Victoza® (Liraglutide Injection 1.8Mg), in the United States Jun 25
Teva Pharmaceutical Industries Limited Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day) May 30
Teva Pharmaceutical Industries Limited Announces Management Changes, Effective June 3, 2024 May 16 Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2024
First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.18 loss in 1Q 2023) May 09 Teva Pharmaceutical Industries Limited, Annual General Meeting, Jun 06, 2024
Teva Confirms Efficacy and Safety of AJOVY for the Prevention of Migraine with Results from Phase 3 Trial in China Apr 11
Teva Pharmaceutical Industries Limited to Report Q1, 2024 Results on May 08, 2024 Apr 10
Full year 2023 earnings released: US$0.50 loss per share (vs US$2.12 loss in FY 2022) Feb 01
Teva Pharmaceutical Industries Limited Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023 Feb 01
Teva Pharmaceutical Industries Limited Announces Earnings Guidance for Full Year 2024 Jan 31
Court for the District of New Jersey Issues A Decision That Teva Pharmaceuticals Does Not Infringe Any Asserted Claims of Corcept Therapeutics Incorporated’s U.S. Patents Jan 02
Teva Pharmaceutical Industries Limited Announces Post Hoc Phase 3 Data Analysis Shows AJOVY (Fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-Morbid Obesity Dec 06
Third quarter 2023 earnings released: EPS: US$0.071 (vs US$0.05 in 3Q 2022) Nov 10
Teva Pharmaceutical Industries Ltd. Appoints R. Ananthanarayanan (Ananth) as CEO of Its Teva Active Pharmaceutical Ingredients Business Nov 08
Teva Pharmaceutical Industries Limited Announces Phase IV Unite Study Shows Ajovy® (Fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder Oct 17
Teva Pharmaceutical Industries Limited to Report Q3, 2023 Results on Nov 08, 2023 Oct 07
Teva Announces Changes to Executive Management Team Sep 29
Teva Pharmaceutical Industries Limited Appoints Varda Shalev as Member of the Board, Effective September 1, 2023 Aug 05 Teva Pharmaceutical Industries Limited Reports Impairment Charges for the Second Quarter Ended June 30, 2023
Second quarter 2023 earnings released: US$0.77 loss per share (vs US$0.21 loss in 2Q 2022) Aug 04
Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development, Effective August 1, 2023 Jul 28
New minor risk - Share price stability Jul 09 Teva Pharmaceutical Industries Limited to Report Q2, 2023 Results on Aug 02, 2023
Teva Pharmaceutical Industries Ltd. Announces Further Positive Data from the Pan-European Research Study Jul 01
Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY Jun 17 Teva Pharmaceuticals Presents Real-World Data for Austedo (Deutetrabenazine) Tablets with 4-Week Patient Titration Kit At Psych Congress Elevate 2023 Jun 03
Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting May 21
Teva Pharmaceutical Industries Limited Announces That Once-Daily Austedoxr (Deutetrabenazine) Extended-Release Tablets Are Now Available for Adults in the United States May 16
Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2023 May 11
First quarter 2023 earnings released: US$0.19 loss per share (vs US$0.86 loss in 1Q 2022) May 11
Full year 2022 earnings released: US$2.12 loss per share (vs US$0.38 profit in FY 2021) Feb 09
Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2023 Feb 09
Teva Pharmaceutical Industries Limited to Report Q4, 2022 Results on Feb 08, 2023 Jan 13
Karo Pharma AB (publ) agreed to acquire of Six brands of Teva for DKK 84 million. Dec 06 Teva Pharmaceutical Industries Limited Appoints Richard Francis as President, Effective January 1, 2023
Third quarter 2022 earnings released: EPS: US$0.05 (vs US$0.27 in 3Q 2021) Nov 05 Teva Pharmaceutical Industries Limited Revises Earnings Guidance for the Year 2022
Teva Pharmaceutical Industries Limited Reaches Agreement with Arkansas to Settle the State’s Price Fixing Claims Oct 08 Teva Pharmaceutical Industries Limited to Report Q3, 2022 Results on Nov 03, 2022 Teva Pharmaceutical Industries Limited Presents Studies of Effectiveness of AJOVY for Treatment of Migraine in Patients with Co-morbid Depression
Exelixis, Inc. Files Complaint in the United States District Court for the District of Delaware for Patent Infringement against Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc Sep 03
Teva Pharmaceutical Industries Limited Announces European Commission Grants Marketing Authorization for Ranivisio (Ranibizumab), for Age-Related Macular Degeneration (AMD) the Most Common Cause of Blindness in Developed Countries Aug 29
Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2022 Jul 29
Teva Pharmaceutical Industries Limited Announces Impairment Charges for the Second Quarter Ended June 30, 2022 Jul 28
Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.19 profit in 2Q 2021) Jul 27
Teva Pharmaceutical Industries Limited Appoints Eric A. Hughes as Executive Vice President, Global R&D and Chief Medical Officer Jul 02
Teva Pharmaceutical Industries Limited to Report Q2, 2022 Results on Jul 27, 2022 Jun 30 Teva Pharmaceutical Industries Limited Welcomes the UK Medicines & Healthcare Regulatory Agency Decision to Grant A Licence for Ongavia May 18
Teva Pharmaceutical Industries Limited Revises Earnings Guidance for the Full Year 2022
First quarter 2022 earnings released: US$0.86 loss per share (vs US$0.07 profit in 1Q 2021) May 04
Teva Pharmaceutical Industries Limited to Report Q1, 2022 Results on May 03, 2022 Apr 05
Investor sentiment improved over the past week Mar 31
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 10
Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2022 Feb 10
Teva Announces Launch of First-To-Market Generic Version of Narcan (Naloxone Hydrochloride Nasal Spray), in the U.S Dec 23
Chief Accounting Officer Andrew Weil has left the company Dec 01
Third quarter 2021 earnings released: EPS US$0.27 (vs US$3.97 loss in 3Q 2020) Oct 28
Teva Pharmaceutical Industries Limited Reaches Agreement with Louisiana to Settle the State’s Opioid-Related Claims Oct 01
Forecast to breakeven in 2021 Sep 23
Executive Vice President of North America Commercial Brendan O'Grady has left the company Aug 18
Executive Vice President of North America Commercial Brendan O'Grady has left the company Aug 18
Insufficient new directors Aug 01
Second quarter 2021 earnings released: EPS US$0.19 (vs US$0.13 in 2Q 2020) Jul 30
Independent Director Abbas Hussain has left the company Jul 15
Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY® (fremanezumab) Injection in Japan for the Preventive Treatment of Migraine in Adults Jun 24
Teva Announces Its Launch of the First Generic Perforomist®, Formoterol Fumarate Inhalation Solution, 20 mcg/2 ML, Used to Treat Chronic Obstructive Pulmonary Disease (COPD), in the United States Jun 23 Teva Pharmaceutical Industries Ltd. Presents Analysis on AJOVY® (fremanezumab) Injection
Executive Vice President of International Markets Commercial Gianfranco Nazzi has left the company May 01
Teva Pharmaceutical Industries Limited Announces the Launch of the First Generic Version of Absorica (Isotretinoin) Capsules, for the Treatment of Severe Recalcitrant Nodular Acne in Patients 12 Years of Age and Older, in the United States Apr 30
First quarter 2021 earnings released: EPS US$0.07 (vs US$0.063 in 1Q 2020) Apr 30 Rendimenti per gli azionisti TEV DE Pharmaceuticals DE Mercato 7D -1.2% -3.5% 2.3% 1Y 35.8% -14.6% 16.7%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: TEV ha superato il German Pharmaceuticals che ha restituito -14.6 % nell'ultimo anno.
Rendimento vs Mercato: TEV ha superato il mercato German che ha restituito 16.7 % nell'ultimo anno.
Volatilità dei prezzi Is TEV's price volatile compared to industry and market? TEV volatility TEV Average Weekly Movement 9.7% Pharmaceuticals Industry Average Movement 5.2% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.5%
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di TEV è stato volatile rispetto al mercato German.
Volatilità nel tempo: La volatilità settimanale ( 10% ) di TEV è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni German.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 1901 34,789 Richard Francis www.tevapharm.com
Teva Pharmaceutical Industries Limited sviluppa, produce, commercializza e distribuisce farmaci generici e di altro tipo e prodotti biofarmaceutici negli Stati Uniti, in Europa, in Israele e a livello internazionale. Offre farmaci generici in varie forme di dosaggio, come compresse, capsule, iniettabili, inalanti, liquidi, cerotti transdermici, unguenti e creme; prodotti sterili, ormoni, farmaci ad alta potenza e sostanze citotossiche in forme di dosaggio parenterali e solide; prodotti generici con dispositivi medici e prodotti combinati. L'azienda si concentra anche sui settori del sistema nervoso centrale (SNC), respiratorio e oncologico.
Mostra di più Teva Pharmaceutical Industries Limited Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Teva Pharmaceutical Industries con la sua capitalizzazione di mercato? TEV statistiche fondamentali Capitalizzazione di mercato €18.42b Guadagni(TTM ) -€1.58b Ricavi(TTM ) €15.99b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) TEV Conto economico (TTM ) Ricavi US$16.54b Costo del fatturato US$8.48b Profitto lordo US$8.06b Altre spese US$9.70b Guadagni -US$1.64b
Ultimi guadagni dichiarati
Dec 31, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -1.45 Margine lordo 48.74% Margine di profitto netto -9.91% Rapporto debito/patrimonio netto 310.9%
Come si è comportato TEV nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/02/11 07:22 Prezzo dell'azione a fine giornata 2025/02/11 00:00 Guadagni 2024/12/31 Guadagni annuali 2024/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github .
Fonti analitiche Teva Pharmaceutical Industries Limited è coperta da 59 analisti. 9 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Jasper Hellweg Argus Research Company Balaji Prasad Barclays Balaji Prasad Barclays
Mostra 56 altri analisti 
